What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?

·3-min read

FibroGen (NASDAQ: FGEN) received some bad news recently with an overwhelmingly negative vote by a U.S. Food and Drug Administration (FDA) advisory committee related to anemia drug roxadustat. In this Motley Fool Live video recorded on July 19, 2021, healthcare and cannabis bureau chief Corinne Cardina and Motley Fool contributor Keith Speights discuss what's next for FibroGen after this disappointing vote.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting